Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    "Noonan syndrome 3"
Show Display Options
Rank Status Study
1 Active, not recruiting Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
Condition: Hepatitis C
Intervention:
2 Not yet recruiting Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Conditions: Viral Hepatitis C;   HIV
Intervention: Drug: Sofosbuvir/Ledipasvir fixed dose
3 Recruiting Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
Conditions: Gaucher Disease;   Hepatitis C
Intervention:
4 Completed Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection
Condition: Hepatitis C
Intervention: Biological: GI-5005
5 Completed
Has Results
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
Condition: Genotype 1 Chronic Hepatitis C
Interventions: Drug: GI-5005;   Drug: Pegylated Interferon and Ribavirin
6 Terminated GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Condition: Chronic Hepatitis C
Interventions: Drug: GS-5885;   Drug: GS-9451;   Drug: RBV;   Drug: PEG

Indicates status has not been verified in more than two years